| abstract |
The present invention relates to a compound of formula (I) wherein X represents a group selected from SO and SO 2 , Y represents a group selected from (CH 2 ) n , NH and NHCH 2 , and n represents , An integer from 0 to 1, Z is H, or alkyl, nitro, halogen, alkoxy, trifluoromethyl, cyano, amino, alkylamino, dialkylamino, aminomethyl, alkylaminomethyl, dialkylaminomethyl, Monosubstituted by hydroxyl, alkylsulfonylamino, R 1 is optionally substituted alkyl, cycloalkyl, phenyl, biphenyl, heterocyclyl and R 2 is optionally substituted phenyl, heterocyclyl Or an NR 3 R 4 group, wherein R 3 and R 4 are independently hydrogen, and optionally substituted R 5 and R 4 selected from the group of alkyl or optionally substituted C 5-7 containing one or more heteroatoms, together with the N atom to which they are attached. Forming a heterocyclyl group), or an NH—CO—R 5 R 6 group, wherein R 5 and R 6 are independently selected from the group of hydrogen, and optionally substituted alkyl, or R 5 And R 6 together with the N atom to which they are attached form an optionally substituted C 5-7 heterocyclyl group containing one or more heteroatoms)] MGluR1 and mGluR5 receptor subtype selective ligands and / or hydrates and / or solvates and / or pharmaceutically acceptable salts thereof formed with acids or bases In relation to methods of producing them, to pharmaceutical compositions containing them, of mGluR1 and mGluR5 receptors, such as neuropathy, psychiatric disorders, acute and chronic pain, lower urinary tract and neuromuscular dysfunction of gastrointestinal diseases It relates to their use in the treatment and / or prevention of pathological conditions that require modulation. |